A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer

A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer - A phase II study of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer (TCOG LC-1202)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009476

Enrollment

Registered

2013-02-01

Start date

2013-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-squamous non-small-cell lung cancer

Interventions

Bevacizumb (15mg/kg day1) + Cislpatin (65mg/m2 day1) + S-1(80mg/m2 day1-14) q3weeks at a target 6cycles(at least 4cycles) followed by Bevacizumab (15mg/kg day1) + S-1(80mg/m2 alternate-day(Mon.Wed.F

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Written IC 2.Patients aged 20-74 years 3.ECOG performance status 0-1 4.Excepted to live over 3 months after administration day 5.Histologically or cytologically confirmed non-squamous non-small-cell lung cancer 6.Stage III/IV or post-operative recurrent disease 7.No prior chemotherapy 8.Target lesion is measurable(RECISTver1.1) 9.Adequate organ function

Exclusion criteria

Exclusion criteria: 1.Symptomatic brain metastases 2.history of active double cancer within 5 years 3.Current history of hemosputum or hemoptysis 4.Have possibly complication related to bleeding episode 5.Receiving anticoagulant drug (including Aspirin over 325mg/day) 6.Great vessel involvement 7.Have received radiation therapy to lesions of lung 8.Pleural effusion,peritoneal fluid, and pericardial fluid 9.Serious complications 10.Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year 11.Uncontrollable Hypertension 12.Interstitial pneumonia or pulmonary fibrosis detectable on X ray 13.Proven or suspected infections diseases 14.Watery diarrhea or Chronic constipation 15.Under treatment by flucytosine 16.Hypersensitivity of Protocol agents 17.History of pregnancy or lactation and no intention to practice birth control 18.Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	—

Secondary

Measure	Time frame
Response Rate Overall Survival Waterfall Plot Analysis Safety Profile Quality of Life	—

Countries

Japan

Contacts

Public ContactTCOG LC OFFICE

The Tokyo cooperative oncology group Clinical Study Promotion Agency

tcog-lc@tcog.jp03-5401-5020

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026